Emergent BioSolutions Analyst Ratings
Emergent BioSolutions Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/20/2023 | — | JP Morgan | Reinstates | → Underweight | |
08/29/2023 | — | Benchmark | Downgrades | Buy → Hold | |
05/31/2023 | 1016.75% | Benchmark | → $22 | Reiterates | Buy → Buy |
05/19/2023 | 1016.75% | Benchmark | → $22 | Reiterates | Buy → Buy |
04/10/2023 | 1016.75% | Benchmark | → $22 | Upgrades | Hold → Buy |
03/17/2023 | 356.85% | JP Morgan | $23 → $9 | Downgrades | Neutral → Underweight |
11/10/2022 | — | Benchmark | Downgrades | Buy → Hold | |
11/09/2022 | 2691.88% | Chardan Capital | $65 → $55 | Maintains | Buy |
09/12/2022 | 1372.08% | Cowen & Co. | $30 → $29 | Maintains | Market Perform |
05/04/2022 | 1828.93% | Wells Fargo | $46 → $38 | Maintains | Equal-Weight |
04/29/2022 | 3199.49% | Chardan Capital | $75 → $65 | Maintains | Buy |
03/10/2022 | 1930.46% | Wells Fargo | $37 → $40 | Maintains | Equal-Weight |
11/10/2021 | 3707.11% | Chardan Capital | $92 → $75 | Maintains | Buy |
11/08/2021 | — | Benchmark | Downgrades | Buy → Hold | |
05/05/2021 | — | Argus Research | Downgrades | Buy → Hold | |
04/30/2021 | 4570.05% | Chardan Capital | $112 → $92 | Maintains | Buy |
04/07/2021 | 7514.21% | Benchmark | → $150 | Initiates Coverage On | → Buy |
02/24/2021 | 5585.28% | Chardan Capital | → $112 | Upgrades | Neutral → Buy |
02/19/2021 | 5585.28% | Chardan Capital | → $112 | Downgrades | Buy → Neutral |
01/08/2021 | — | Wells Fargo | Downgrades | Overweight → Equal-Weight | |
07/31/2020 | 5585.28% | Chardan Capital | $86 → $112 | Maintains | Buy |
07/17/2020 | 5483.76% | Cantor Fitzgerald | $85 → $110 | Maintains | Overweight |
06/08/2020 | 4214.72% | Cantor Fitzgerald | $86 → $85 | Maintains | Overweight |
05/06/2020 | 4468.53% | Argus Research | $67 → $90 | Maintains | Buy |
05/01/2020 | 4265.48% | Cantor Fitzgerald | $75 → $86 | Maintains | Overweight |
05/01/2020 | 4265.48% | Chardan Capital | $71 → $86 | Maintains | Buy |
04/30/2020 | 4214.72% | Wells Fargo | $75 → $85 | Maintains | Overweight |
02/25/2020 | 3707.11% | Wells Fargo | $66 → $75 | Maintains | Overweight |
09/12/2019 | 3199.49% | Guggenheim | → $65 | Initiates Coverage On | → Buy |
09/04/2019 | 3148.73% | Wells Fargo | $61 → $64 | Upgrades | Market Perform → Outperform |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
11/20/2023 | — | 摩根大通 | 恢復 | → 體重不足 | |
08/29/2023 | — | 基準 | 降級 | 買入 → 持有 | |
05/31/2023 | 1016.75% | 基準 | → 22 美元 | 重申 | 購買 → 購買 |
05/19/2023 | 1016.75% | 基準 | → 22 美元 | 重申 | 購買 → 購買 |
2023 年 10 月 4 日 | 1016.75% | 基準 | → 22 美元 | 升級 | 持有 → 買入 |
03/17/2023 | 356.85% | 摩根大通 | 23 美元 → 9 美元 | 降級 | 中性 → 體重不足 |
2022 年 10 月 11 日 | — | 基準 | 降級 | 買入 → 持有 | |
11/09/2022 | 2691.88% | 查丹資本 | 65 美元 → 55 美元 | 維護 | 買 |
09/12/2022 | 1372.08% | Cowen & Co. | 30 美元 → 29 美元 | 維護 | 市場表現 |
05/04/2022 | 1828.93% | 富國銀行 | 46 美元 → 38 美元 | 維護 | 重量相等 |
2022 年 4 月 29 日 | 3199.49% | 查丹資本 | 75 美元 → 65 美元 | 維護 | 買 |
03/10/2022 | 1930.46% | 富國銀行 | 37 美元 → 40 美元 | 維護 | 重量相等 |
11/10/2021 | 3707.11% | 查丹資本 | 92 美元 → 75 美元 | 維護 | 買 |
2021 年 8 月 11 日 | — | 基準 | 降級 | 買入 → 持有 | |
2021 年 5 月 5 日 | — | 阿格斯研究 | 降級 | 買入 → 持有 | |
04/30/2021 | 4570.05% | 查丹資本 | 112 美元 → 92 美元 | 維護 | 買 |
2021 年 7 月 4 日 | 7514.21% | 基準 | → 150 美元 | 啓動覆蓋範圍開啓 | → 購買 |
2021 年 2 月 24 日 | 5585.28% | 查丹資本 | → 112 美元 | 升級 | 中性 → 買入 |
02/19/2021 | 5585.28% | 查丹資本 | → 112 美元 | 降級 | 買入 → 中性 |
01/08/2021 | — | 富國銀行 | 降級 | 超重 → 重量相等 | |
07/31/2020 | 5585.28% | 查丹資本 | 86 美元 → 112 美元 | 維護 | 買 |
07/17/2020 | 5483.76% | 坎託·菲茨傑拉德 | 85 美元 → 110 美元 | 維護 | 超重 |
06/08/2020 | 4214.72% | 坎託·菲茨傑拉德 | 86 美元 → 85 美元 | 維護 | 超重 |
2020 年 6 月 5 日 | 4468.53% | 阿格斯研究 | 67 美元 → 90 美元 | 維護 | 買 |
05/01/2020 | 4265.48% | 坎託·菲茨傑拉德 | 75 美元 → 86 美元 | 維護 | 超重 |
05/01/2020 | 4265.48% | 查丹資本 | 71 美元 → 86 美元 | 維護 | 買 |
04/30/2020 | 4214.72% | 富國銀行 | 75 美元 → 85 美元 | 維護 | 超重 |
2020 年 2 月 25 日 | 3707.11% | 富國銀行 | 66 美元 → 75 美元 | 維護 | 超重 |
2019 年 12 月 9 日 | 3199.49% | 古根海姆 | → 65 美元 | 啓動覆蓋範圍開啓 | → 購買 |
09/04/2019 | 3148.73% | 富國銀行 | 61 美元 → 64 美元 | 升級 | 市場表現 → 跑贏大盤 |
What is the target price for Emergent BioSolutions (EBS)?
Emergent BioSolutions(EBS)的目標價格是多少?
The latest price target for Emergent BioSolutions (NYSE: EBS) was reported by JP Morgan on November 20, 2023. The analyst firm set a price target for $0.00 expecting EBS to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.
摩根大通於2023年11月20日公佈了Emergent BioSolutions(紐約證券交易所代碼:EBS)的最新目標股價。該分析公司將目標股價定爲0.00美元,預計EBS將在12個月內跌至12個月內(可能下跌-100.00%)。去年有6家分析公司公佈了評級。
What is the most recent analyst rating for Emergent BioSolutions (EBS)?
Emergent BioSolutions(EBS)的最新分析師評級是多少?
The latest analyst rating for Emergent BioSolutions (NYSE: EBS) was provided by JP Morgan, and Emergent BioSolutions their underweight rating.
摩根大通對Emergent BioSolutions(紐約證券交易所代碼:EBS)的最新分析師評級由摩根大通提供,Emergent BioSolutions提供了減持評級。
When is the next analyst rating going to be posted or updated for Emergent BioSolutions (EBS)?
Emergent BioSolutions(EBS)的下一份分析師評級何時發佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Emergent BioSolutions, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Emergent BioSolutions was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與Emergent BioSolutions的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級,因此每家公司每年應該獲得4次評級。Emergent BioSolutions的最新評級是在2023年11月20日公佈的,因此您應該預計下一個評級將在2024年11月20日左右公佈。
Is the Analyst Rating Emergent BioSolutions (EBS) correct?
分析師對Emergent BioSolutions(EBS)的評級正確嗎?
While ratings are subjective and will change, the latest Emergent BioSolutions (EBS) rating was a with a price target of $0.00 to $0.00. The current price Emergent BioSolutions (EBS) is trading at is $1.97, which is out of the analyst's predicted range.
儘管評級是主觀的,並且會發生變化,但最新的Emergent BioSolutions(EBS)評級爲A,目標股價爲0.00美元至0.00美元。Emergent BioSolutions(EBS)目前的交易價格爲1.97美元,超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。